Solid Biosciences Inc.
$8.49
▲
1.49%
2026-04-21 09:27:01
www.solidbio.com
NMS: SLDB
Explore Solid Biosciences Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$835.34 M
Current Price
$8.49
52W High / Low
$8.87 / $2.41
Stock P/E
—
Book Value
$2.28
Dividend Yield
—
ROCE
-90.02%
ROE
-1.1%
Face Value
—
EPS
$-1.99
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
121
Beta
2.58
Debt / Equity
11.76
Current Ratio
6.14
Quick Ratio
6.14
Forward P/E
-4.76
Price / Sales
—
Enterprise Value
$622.41 M
EV / EBITDA
-3.5
EV / Revenue
—
Rating
None
Target Price
$17.08
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Aspire Biopharma Holdings, Inc. | $0.26 | — | $1.36 M | — | 308.11% | 618.48% | $35 / $0.22 | $-1.8 |
| 2. | Surrozen, Inc. | $32.25 | — | $362.52 M | — | -47.4% | 231.45% | $33.22 / $5.9 | $-19.21 |
| 3. | Biomea Fusion, Inc. | $2.05 | — | $159.78 M | — | -171.28% | -1.52% | $3.08 / $0.87 | $0.41 |
| 4. | Spruce Biosciences, Inc. | $69.89 | — | $96.45 M | — | -85.04% | -1.09% | $240 / $4.28 | $30.99 |
| 5. | UroGen Pharma Ltd. | $24.92 | — | $1.21 B | — | -81.06% | 268.63% | $30 / $3.42 | $-2.18 |
| 6. | Silo Pharma, Inc. | $0.67 | — | $8.38 M | — | -61.55% | -74.57% | $1.19 / $0.22 | $0.47 |
| 7. | Krystal Biotech, Inc. | $276.4 | 40.42 | $8.11 B | — | 13.1% | 18.91% | $298.3 / $122.8 | $41.78 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -49.4 M | -48.06 M | -41.69 M | -40.05 M | -39.9 M | — |
| Net Profit | -49.79 M | -45.78 M | -39.48 M | -39.28 M | -42.6 M | — |
| EPS in Rs | -0.51 | -0.47 | -0.4 | -0.4 | -0.43 | -0.79 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 8.09 M |
| Operating Profit | -179.21 M | -129.73 M | -104.31 M | -99.27 M |
| Net Profit | -174.32 M | -124.7 M | -96.02 M | -85.98 M |
| EPS in Rs | -1.77 | -1.27 | -0.98 | -0.87 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 232.54 M | 188.66 M | 164.94 M | 260.25 M |
| Total Liabilities | 52.53 M | 51.42 M | 38.46 M | 48.59 M |
| Equity | 180.01 M | 137.25 M | 126.48 M | 211.67 M |
| Current Assets | 205.46 M | 157.3 M | 129.73 M | 219.64 M |
| Current Liabilities | 33.47 M | 30.26 M | 14.52 M | 22.51 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -156.29 M | -100.01 M | -94.18 M | -97.98 M |
| Investing CF | -58.45 M | -16.09 M | 9.69 M | 59.16 M |
| Financing CF | 194.45 M | 122.44 M | 3.12 M | 74.83 M |
| Free CF | -157.44 M | -100.67 M | -95.69 M | -100.99 M |
| Capex | -1.15 M | -0.65 M | -1.51 M | -3.02 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | -100% | — | — |
| Earnings Growth % | -29.87% | -11.67% | — | — |
| Profit Margin % | — | — | -1062.28% | — |
| Operating Margin % | — | — | -1226.51% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | -1196.76% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2022-10-28 | 1:0.0666667 |